Khiron, a Colombian company, will enter the market with medicinal cannabis

In the medium term, Khiron seeks to reach more than 68 million patients in Latin America, who could benefit from the prescription of medicinal cannabis.

After obtaining the full licenses to cultivate, produce and distribute cannabis for medicinal use, Khiron Colombia SAS, a subsidiary of Canadian Khiron Life Sciences Corp, is prepared to meet the needs of 5 million patients in Colombia with diverse medical conditions such as epilepsy, multiple sclerosis, neuropathic pain and nausea caused by chemotherapy.

“Although the world has seen Colombia mainly as a producer and exporter of raw material due to the ideal climatic conditions for cultivation, for our shareholders there is a high potential in the domestic market, as well as in the other countries of Latin America, which present an important opportunity for medicinal cannabis, " said Álvaro Torres, CEO of Khiron.

In this sense, Khiron will develop local industries providing scientific expertise, access to capital markets and first level medical credibility to specialists and patients to ensure that "these industries are developed correctly, in a dutiful and safe way for patients"

Together with the medical community, Khiron carries out the necessary education on the proper use of medicinal cannabis, in order to guarantee that the products that are launched on the market respond 100% to the needs of patients.

Together with the Colombian Association of Neurology, the raising of awareness of medicinal cannabis has begun through different initiatives.

“We believe that we have a winning strategy to create loyalty toward patients and doctors in the long term and to lead this industry in Colombia and the region," said the executive.